# NAVIGATE (NCT02576431)

> A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02576431
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Bayer
- Conditions: Solid Tumors Harboring NTRK Fusion
- Interventions: BAY2757556 (Larotrectinib, Vitrakvi)
- Enrollment: 215
- Primary outcome: Best overall response of confirmed complete response (CR) or partial response (PR) as determined by an independent radiology review committee using RECIST v1.1 or RANO criteria, as appropriate to tumor type.

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=navigate-nct02576431